Literature DB >> 7102303

The ozena problem. Clinical analysis of atrophic rhinitis in 100 cases.

C Han-Sen.   

Abstract

One hundred cases of ozena were analysed. The majority of cases were youths (86%). 50% of 33 patients had abnormal menstruation. Löwenberg's bacillus were found in most cases. The middle concha was a frequent side of this affection in our series, 25 cases of accessory sinusitis were found by roentgenographic examination of 35 cases of atrophic rhinitis. 24 cases underwent a serum cholesterol test. This revealed hypocholesterolemia in cases (50%) with an average value of 73.6 mg/100 ml. A large dose of vitamin (12500-150000 U daily or injected vitamin A 50000 U i.m. every other day or water-soluble vitamin A 300000 U twice a week) was generally favourable in most cases. Streptomycin had a beneficial result in sensitive cases. Complete cure of the disease was expected from the combined treatment with vitamin A and streptomycin. No recurrence was found in the majority of cases over a 2-year period of follow-up studies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7102303     DOI: 10.3109/00016488209130905

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  3 in total

1.  Clinical, genetic and immunologic analysis of a family affected by ozena.

Authors:  Lucia Medina; Marco Benazzo; Giulia Bertino; Carlo Maurizio Montecucco; Cesare Danesino; Miryam Martinetti; Eugenio Mira
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-03-26       Impact factor: 2.503

2.  Novel treatment of atrophic rhinitis: early results.

Authors:  Abhishek Jaswal; Avik Kumar Jana; Biswajit Sikder; Tapan K Nandi; Sanjoy Kumar Sadhukhan; Anjan Das
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-04       Impact factor: 2.503

3.  Primary atrophic rhinitis: a clinical profile, microbiological and radiological study.

Authors:  Sampan S Bist; Manisha Bisht; Jagdish P Purohit
Journal:  ISRN Otolaryngol       Date:  2012-11-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.